

Midkine Portfolio Update – November 2025

4 November 2025

Anagenics Limited (ASX:AN1, “Anagenics” or the “Company”) today provides an update on its Midkine intellectual property portfolio.

Background

Anagenics has an intellectual property license agreement (the “Licence Agreement”) with Lynamid Pty Ltd, which was acquired by Roquefort Therapeutics in late 2021. Under this agreement, Anagenics is entitled to receive royalties from products utilising its Midkine intellectual property portfolio. This includes a 4% royalty on net sales of products developed and sold, and an 8% royalty on net sub licensing revenue.

On 2 January 2025, Roquefort Therapeutics announced the signing of a term sheet for the sale of Lynamid to Pleiades Pharma Limited (the “Transaction”), with completion “contingent inter alia on Pleiades completing a current fundraising round and finalising certain in-licensing transactions”.

On 30 September 2025, Roquefort Therapeutics indicated a long stop date of 31 October 2025 for the Transaction to complete, with a key closing condition that Pleiades complete a fundraising round by 31 October 2025.

On 3 November 2025, Roquefort Therapeutics announced the long stop date of 31 October 2025 is to be extended to 31 January 2026.

Update

The Licence Agreement was for a term of five years, ending 1 August 2025, from which date Anagenics can terminate the Licence Agreement after providing 90 days’ notice.

Anagenics has provided that notice, with the Licence Agreement terminating on 2 November 2025.

Anagenics will now work with Roquefort Therapeutics to have all Midkine products and intellectual property returned, with the Company now free to further commercialise the Midkine product range.

This announcement was authorised by the Board of Anagenics Limited.

For further information, please contact:

Sandy Beard
Chair, Anagenics Limited
P: 0412 308 263
E: sandy@xvgroup.com.au

Anagenics Limited (ASX:AN1)

Anagenics is a health, beauty, and wellness business growing shareholder value through the global distribution and sales of its proprietary and licensed brands of differentiated, clinically validated anti-aging solutions. BLC Cosmetics Pty Ltd is Anagenics' wholly owned subsidiary focused on sales and distribution of leading Australian and international brands of cosmetic and wellness products.

For further information, please see www.anagenics.com